Enzene Biosciences Ltd

Looking forward to a power-packed panel discussion at Harvard University featuring our CEO, Himanshu Gadgil, PhD, who will share insights on innovation, including our Fully-Connected Continuous Manufacturing™ technology and how it is disrupting traditional manufacturing to impact patient lives. #Harvard #innovation #STEM #biopharma

CMC is often cited as the bottleneck for conjugated therapeutics. It doesn’t need to be. Conjugated therapeutic proteins are gaining momentum across oncology, infectious diseases, and autoimmune indications. Yet many programs slow down at the CMC stage, driven by concerns around process complexity, control, and scalability. In practice, those concerns can be addressed early. With well-designed upstream (fed-batch or perfusion) and an integrated downstream strategy, conjugation workflows can be developed to deliver consistent quality and manufacturing readiness—without adding unnecessary risk. At Enzene, the focus is on building CMC foundations that support reproducibility, efficient scale-up, and timely progression to the clinic and beyond. Learn more here: https://lnkd.in/dPBdCcEZ #CMC #ConjugatedTherapeutics #Bioprocessing #Biomanufacturing #Biopharma #ProcessDevelopment #MSAT

As the CDMO industry evolves, biologics manufacturing is shifting toward personalized therapies, localized supply, and away from large, centralized facilities toward compact, high-intensity manufacturing models. In ARTO’s Making it in Manufacturing – 2026 podcast with Thomas McMann, our CEO, Himanshu Gadgil, PhD, shares how next-generation CDMOs will need to evolve and enable: • Personalized and niche biologics without sacrificing scalability • Localized manufacturing to improve supply resilience and speed to patients • Large-scale output delivered through compact, modular facilities • Fully-connected continuous and integrated manufacturing as the new operational baseline #MakingItInManufacturing #Podcast #BiologicsManufacturing #CDMO

Scalable synthetic peptide manufacturing—from discovery to clinic. Synthetic peptides are gaining momentum as therapeutics, offering high specificity, low immunogenicity, and reduced off-target effects for complex disease indications. Enzene delivers high-quality synthetic peptides with deep scientific expertise and scalable, GMP-ready capabilities. Capabilities across the peptide lifecycle • Solid, solution & hybrid-phase peptide synthesis • Process development from mg to multigram scale • Long-chain (up to 40 AA), cyclic, modified & disulfide-bridged peptides • Post-translational modifications including PEGylation & biotinylation • Preparative RP-HPLC purification and large-scale lyophilization • GMP manufacturing and tech transfer for clinical programs Infrastructure built for scale ✔ Fully automated 200L peptide synthesizer ✔ Manual reactors (100 mL–20 L) ✔ High-capacity preparative HPLC systems ✔ Industrial lyophilization and controlled storage From early development to clinical supply, Enzene supports efficient, reliable peptide manufacturing. 👉 Connect to discuss your synthetic peptide requirements: https://lnkd.in/d-3yvqJp #SyntheticPeptides #PeptideSynthesis #Biotech #Pharma #CDMO #GMP #ProcessDevelopment #DrugDevelopment

Proud to share that Enzene has been recognized as a @Great Place to Work® in India for the 5th year in a row. This milestone reflects the trust our people place in one another, the ownership they bring to their work, and a culture built on learning, collaboration, and purpose—with a shared focus on creating meaningful impact for patients. All guided by our core values: Candor, Excellence, Entrepreneurship, Integrity, Innovation, Respect   Grateful to our teams for shaping Enzene into a workplace where people thrive, innovation advances, and patient impact remains at the center.   We Are Enzene. Lata Kumar Great Place To Work India #GreatPlaceToWork #GPTWIndia #LifeAtEnzene #WeAreEnzene #WorkplaceCulture #PatientImpact #5YearsInARow

Scaling biologics brings risk, delays, and cost pressures—but it doesn’t have to. Enzene’s 80,000 sq. ft. New Jersey facility is built for Phase 1 through commercial scale, with 200L–1000L bioreactors, fed-batch and FCCM™ (EnzeneX™ 2.0), modular suites, and integrated DS, DP, and CMC/QC capabilities. Book a meeting to explore a predictable, efficient path to biologics manufacturing: https://us.enzene.com/home Norm Stoffregen, Lucy Lavallee, Russell Miller, Yukhti Yachha, Jin Kim, Kumar Bala #biologics #NewJersey #CDMO

India’s 2026–27 Union Budget places biopharmaceuticals at the centre of India’s advanced manufacturing ambitions through the Biopharma SHAKTI initiative. It’s an exciting moment for the sector, and for Enzene, it presents a real opportunity to contribute to this growing ecosystem. Reflecting on this, our CEO, Himanshu Gadgil, PhD, shares: "With the beginning of February came the presentation of India’s 2026–27 Union Budget, which places biopharmaceuticals at the centre of the country’s strategy to scale up advanced manufacturing through the Biopharma SHAKTI initiative — a ₹10,000 crore programme to strengthen research, talent, clinical trials, and the production of biologics and biosimilars. I am excited about the opportunity for Enzene to contribute to this ecosystem-building agenda through our flexible and scalable fully-connected continuous manufacturing™ (FCCM™) technology, as well as partnerships that support skills development and meaningful industry–academia collaboration. Over the last few years, Enzene has already contributed to the Indian healthcare and manufacturing ecosystem through the approval of eight biosimilars, supporting more than 60 brands in the country, and by demonstrating global leadership in continuous manufacturing via EnzeneX™, enabling significant reductions in the cost of biologics manufacturing and expanding patient access." Nirmala Sitharaman, Department of Biotechnology, Department of Pharmaceuticals Invest India, NITI Aayog Official Department Of Economic Affairs, Government Of India, Biotechnology Industry Research Assistance Council (BIRAC), Central Drugs Standard Control Organization #UnionBudget2026 #UnionBudget #Biologics #Biosimilars #BiopharmaSHAKTI #EnzeneX

Scale-up risk is the hidden cost in animal health innovation. As we attend the Animal Health, Nutrition & Technology Innovation Europe 2026 in London, we are sharing with you how animal health teams can embed manufacturability, cost, and supply considerations early in development. Our brochure highlights: ● Integrated development and manufacturing pathways for complex biologics ● Case study ● Approaches to reduce scale-up risk, strengthen process robustness, and enable smoother tech transfer ● A disciplined focus on quality, consistency, and long-term commercial supply 📅 Message our team to book a meeting with them and discuss your R&D, CMC, or manufacturing strategy. Our team at the event: Himanshu Gadgil, PhD, Russell Miller, Wouter Huizinga, Shilpa Gadgil, PhD, Sushil Momaya #AHNTI #AnimalHealth

Top 10 Biosimilars to Start Developing Today | #4: Benralizumab Severe eosinophilic asthma remains uncontrolled for a significant patient subset—driving frequent exacerbations, hospitalizations, and long-term biologic use. With LOE expected between 2029–2031, Benralizumab presents a compelling biosimilar opportunity. But success depends on precise afucosylation control, robust ADCC functional comparability, and early CMC readiness—especially in a chronic dosing setting. 👉 Swipe to see why Benralizumab ranks #4 and what raises the execution bar. We’re counting down in reverse. Disclaimer - This material is intended for informational industry discussion only. Any reference to innovator products or trademarks is only for market context and does not imply endorsement, affiliation, promotion, or comparative claims. Himanshu Gadgil, PhD, Russell Miller, Jin Kim, Yukhti Yachha, Sushil Momaya, Kumar Bala, Shilpa Gadgil, PhD, Abijar Bhori, Nildip Chauhan, Anant Suri, Nikita B. #Top10Biosimilars #CDMO #biosimilars

Path to Glory at Enzene — Inspiring Minds, Igniting Possibilities. At Enzene, we believe growth happens when curiosity meets opportunity. Our "Path to Glory" sessions are designed exactly for that purpose—bringing extraordinary thinkers to spark new perspectives, inspire courage, and strengthen our culture of continuous learning. On January 15th, we had the honour of hosting Dr. Narendra Chirmule, a renowned scientist, educator, and Co‑founder of Symphony Technologies. His journey—spanning vaccine development, biologics, cell‑and‑gene therapies, and decades of scientific exploration—reminded us that innovation is never accidental; it is built through resilience, purpose, and relentless pursuit of better solutions. Key themes from the session included: • How science and AI together are redefining drug development • The evolving relationship between human intelligence and artificial intelligence • The role of curiosity in driving discovery and progress • Reflections on life, purpose, and leadership in science • His journey to building Symphony Technologies What made the session impactful was not just the insights shared, but how strongly they resonated with our people. The conversation moved beyond technology—into reflections on purpose, responsibility, and the future role of humans in an AI-driven world. The depth of engagement during the Q&A highlighted what defines Enzene: a culture where learning is valued, perspectives are challenged, and individuals are encouraged to think beyond their roles. Sessions like these reaffirm our commitment to: • Building a culture of continuous learning • Nurturing curiosity as a leadership capability • Empowering every Enzeneite to grow, lead, and create lasting impact on global healthcare Lata Kumar #LifeAtEnzene #LearningCulture #Leadership #Innovation #WeAreEnzene